Tech2Heal SAS, a subsidiary of AI/ML Innovations Inc., has marked a significant milestone by securing its second clinical trial contract for the "My Health Friend" project. This groundbreaking initiative, a collaborative effort between French and Italian University Hospitals, is funded by a European Commission fund. The project aims to revolutionize preventative healthcare, targeting populations in remote areas with limited access to in-person healthcare services.

At the core of this pioneering endeavor is Tech2Heal's proprietary Alakin Platform, a versatile care pathway builder. The platform will support the My Health Friend mobile health application, available in English, French, and Italian, breaking down language barriers and ensuring accessibility for a wide demographic.

This innovative application empowers users with personalized digital rehabilitation programs tailored to their specific needs, enhancing their well-being. Additionally, the Alakin clinical dashboard enables healthcare teams to remotely monitor patients, maintaining a high standard of care regardless of geographical distance.

The trial's primary objectives include gathering data on user satisfaction and usage levels, with a focus on the general population across the transalpine territories of France and Italy. The trial will encompass 1000-1500 individuals over an 18-month period, ensuring robust and comprehensive results. Furthermore, the trial aims to assess the impact of the application on participants' well-being and quality of life over a 6-month period.

This collaboration between Tech2Heal, French and Italian University Hospitals, and the European Commission represents a significant step forward in leveraging technology for improved healthcare accessibility and outcomes, particularly in regions with limited access to traditional healthcare services. The "My Health Friend" project is poised to make a lasting impact on preventative healthcare practices.

View Original Release: https://www.accesswire.com/794106/aiml-innovations-incs-subsidiary-chosen-as-the-digital-technology-provider-for-an-international-clinical-study-funded-by-european-commission